[go: up one dir, main page]

BE904831A - Composition d'activateur tissulaire du plasminogene. - Google Patents

Composition d'activateur tissulaire du plasminogene.

Info

Publication number
BE904831A
BE904831A BE0/216712A BE216712A BE904831A BE 904831 A BE904831 A BE 904831A BE 0/216712 A BE0/216712 A BE 0/216712A BE 216712 A BE216712 A BE 216712A BE 904831 A BE904831 A BE 904831A
Authority
BE
Belgium
Prior art keywords
amino acid
activator composition
tissue activator
plasminogen tissue
acid sequence
Prior art date
Application number
BE0/216712A
Other languages
English (en)
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB858513358A external-priority patent/GB8513358D0/en
Priority claimed from GB858521704A external-priority patent/GB8521704D0/en
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of BE904831A publication Critical patent/BE904831A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Solution aqueuse parentérale d'un pH de 2 à 5 contenant du t-PA mono- ou bicaténaire qui a la séquence des aminoacides à laFig. 1 ou a la meme séquence des aminoacides, mais dont l'aminoacide à la position 245 à partir de l'extrémité N-terminale de la sérine est la valine au lieu de la méthionine, l'une ou l'autre séquence étant éventuellement exempte de l'un quelconque des trois premiers aminoacides ou comprenant éventuellement une préséquence de Gly-Ala-Arg supplémentaire N-terminale du polypeptide.
BE0/216712A 1985-05-28 1986-05-27 Composition d'activateur tissulaire du plasminogene. BE904831A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB858513358A GB8513358D0 (en) 1985-05-28 1985-05-28 Formulation
GB858521704A GB8521704D0 (en) 1985-08-31 1985-08-31 Formulation

Publications (1)

Publication Number Publication Date
BE904831A true BE904831A (fr) 1986-11-27

Family

ID=26289289

Family Applications (1)

Application Number Title Priority Date Filing Date
BE0/216712A BE904831A (fr) 1985-05-28 1986-05-27 Composition d'activateur tissulaire du plasminogene.

Country Status (22)

Country Link
US (1) US5112609A (fr)
AT (1) AT391812B (fr)
AU (1) AU569429B2 (fr)
BE (1) BE904831A (fr)
CA (1) CA1297008C (fr)
CH (1) CH664495A5 (fr)
DE (1) DE3617753A1 (fr)
DK (1) DK163174C (fr)
ES (1) ES8706443A1 (fr)
FI (1) FI85334C (fr)
FR (1) FR2593393B1 (fr)
GB (1) GB2176703B (fr)
GR (1) GR861365B (fr)
HU (1) HU200695B (fr)
IL (1) IL78937A (fr)
IT (1) IT1191925B (fr)
LU (1) LU86445A1 (fr)
NL (1) NL8601354A (fr)
NO (1) NO171344C (fr)
NZ (1) NZ216306A (fr)
PT (1) PT82647B (fr)
SE (1) SE462893B (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI831484L (fi) * 1982-05-05 1983-11-06 Genentech Inc Plasminogen aktivator foer maenskovaevnad
US5185259A (en) * 1982-05-05 1993-02-09 Genentech, Inc. Truncated human tissue plasminogen activator
KR840004781A (ko) * 1982-05-05 1984-10-24 월터 에이치·드레거 인체의 조직 플라스미노겐 활성화제
ATE80306T1 (de) * 1985-03-06 1992-09-15 Survival Technology Mittel zur absorptionsverbesserung von proteinen.
ZW14486A1 (en) * 1985-07-29 1986-10-22 Smithkline Beckman Corp Pharmaceutical dosage unit
US4777043A (en) * 1985-12-17 1988-10-11 Genentech, Inc. Stabilized human tissue plasminogen activator compositions
US5034225A (en) * 1985-12-17 1991-07-23 Genentech Inc. Stabilized human tissue plasminogen activator compositions
BE1001425A4 (fr) * 1986-05-12 1989-10-31 Wellcome Found Utilisation de l'activateur tissulaire du plasminogene, son association avec une superoxyde-dismutase et formulation pharmaceutique contenant cette association.
US4976959A (en) * 1986-05-12 1990-12-11 Burroughs Wellcome Co. T-PA and SOD in limiting tissue damage
GB8619098D0 (en) * 1986-08-05 1986-09-17 Wellcome Found Combination
US5149533A (en) * 1987-06-04 1992-09-22 Zymogenetics, Inc. Modified t-PA with kringle-/replaced by another kringle
US5270198A (en) * 1988-05-20 1993-12-14 Genentech, Inc. DNA molecules encoding variants of tissue plasminogen activators, vectors, and host cells
GB8814604D0 (en) * 1988-06-20 1988-07-27 Wellcome Found Medicaments
WO1990001334A1 (fr) * 1988-08-05 1990-02-22 Codon Formules d'activateur du plasminogene a base d'aspartate
GB8819607D0 (en) * 1988-08-17 1988-09-21 Wellcome Found Novel combination
US5262170A (en) * 1988-09-02 1993-11-16 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties and substituted at amino acid positions 296-299, DNA molecules encoding them, vectors, and host cells
US5714145A (en) * 1988-09-02 1998-02-03 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties
US4980165A (en) * 1989-01-27 1990-12-25 Genetics Institute, Inc. Pharmaceutical formulations of plasminogen activator proteins
DE3942142A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh Stabilisierung von glykosyliertem t-pa
GB9000629D0 (en) * 1990-01-11 1990-03-14 Porton Prod Ltd Tissue plasminogen activator
WO1993024635A1 (fr) * 1992-06-03 1993-12-09 Genentech, Inc. Variantes d'activateur de plasminogene tissulaire obtenues par glycosylation, presentant de meilleures proprietes therapeutiques
US6139838A (en) * 1996-09-06 2000-10-31 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Tissue plasminogen activator medicinal composition
US7544500B2 (en) 1999-11-13 2009-06-09 Talecris Biotherapeutics, Inc. Process for the production of a reversibly inactive acidified plasmin composition
US6355243B1 (en) 1999-11-13 2002-03-12 Bayer Corporation Method of thrombolysis by local delivery of active plasmin
WO2003022997A2 (fr) * 2001-09-07 2003-03-20 Global Biotech Inc. Formulation contenant un activateur de plasminogene de type urokinase de tissu humain
KR20160110544A (ko) * 2008-06-04 2016-09-21 그리폴스 테라퓨틱스 인코포레이티드 플라스민의 제조를 위한 조성물, 방법 및 키트
PL2403865T3 (pl) 2009-03-03 2016-01-29 Grifols Therapeutics Inc Sposoby wytwarzania plazminogenu

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3998947A (en) * 1973-11-30 1976-12-21 Pierre Fabre S.A. Process for obtaining a plasminogen activator
FR2252842B1 (fr) * 1973-12-03 1977-11-04 Fabre Sa Pierre
DE3015699C2 (de) * 1979-04-26 1982-07-15 Asahi Kasei Kogyo K.K., Osaka Herstellung eines Plasminogen-Aktivators
CA1154671A (fr) * 1979-07-27 1983-10-04 Lucien D. D'hinterland Separation d'un activateur tissulaire du plasminogene
NL8003402A (nl) * 1980-06-11 1982-01-04 Leuven Res & Dev Vzw Nieuwe plasminogeen-activator en farmaceutisch preparaat met trombolytische werking.
ZA831399B (en) * 1982-03-05 1984-02-29 Health Lab Service Board New fibrinolytic enzymes and methods for their production and pharmaceutical compositions containing them
GR79202B (fr) * 1982-05-05 1984-10-22 Genentech Inc
JPS5951220A (ja) * 1982-08-02 1984-03-24 Asahi Chem Ind Co Ltd 新規なプラスミノ−ゲン・アクチベ−タ−およびその製法ならびにこれを含有する薬剤
GB2138824B (en) * 1982-10-29 1986-12-31 Mitsui Toatsu Chemicals Novel plasminogen activator process for its preparation and thrombolytic drug containing the same
AU554862B2 (en) * 1982-12-14 1986-09-04 Implico B.V. Plasminogen activator isolated by affinity chromatography
DE3382389D1 (de) * 1982-12-14 1991-10-02 South African Inventions Plasminogenaktivator.
JPS59196824A (ja) * 1983-04-21 1984-11-08 Kowa Co 吸着防止剤
EP0156169B1 (fr) * 1984-02-29 1991-12-18 Asahi Kasei Kogyo Kabushiki Kaisha Solution aqueuse d'un activateur tissulaire du plasminogène dissous à une concentration élevée et un procédé d'obtention
DE3439980A1 (de) * 1984-11-02 1986-05-07 Behringwerke Ag, 3550 Marburg Verfahren zur reinigung sowie pasteurisierung von urokinase
US4929444A (en) * 1985-05-28 1990-05-29 Burroughs Wellcome Co. Low pH pharmaceutical formulation containing t-PA
ZW14486A1 (en) * 1985-07-29 1986-10-22 Smithkline Beckman Corp Pharmaceutical dosage unit
JPH0672105B2 (ja) * 1985-10-02 1994-09-14 持田製薬株式会社 血栓溶解剤及びその製法
DE59009964D1 (de) * 1989-09-13 1996-01-25 Rieter Ag Maschf Verfahren zum Starten eines Arbeitsablaufs eines Bedienungsautomaten an einer Textilmaschine

Also Published As

Publication number Publication date
AU5796586A (en) 1986-12-04
LU86445A1 (fr) 1986-12-05
IT1191925B (it) 1988-03-31
NO862095L (no) 1986-12-01
AT391812B (de) 1990-12-10
IT8648064A0 (it) 1986-05-27
FI862226L (fi) 1986-11-29
HUT42330A (en) 1987-07-28
NO171344B (no) 1992-11-23
CH664495A5 (de) 1988-03-15
GR861365B (en) 1986-09-29
FR2593393A1 (fr) 1987-07-31
DK163174B (da) 1992-02-03
FI85334C (fi) 1992-04-10
AU569429B2 (en) 1988-01-28
NO171344C (no) 1993-03-03
SE8602404L (sv) 1986-11-29
SE8602404D0 (sv) 1986-05-27
CA1297008C (fr) 1992-03-10
ATA141186A (de) 1990-06-15
ES555352A0 (es) 1987-07-01
DK246886A (da) 1986-11-29
FI862226A0 (fi) 1986-05-27
IL78937A (en) 1990-11-29
NZ216306A (en) 1989-10-27
SE462893B (sv) 1990-09-17
PT82647A (en) 1986-06-01
DK246886D0 (da) 1986-05-27
US5112609A (en) 1992-05-12
IL78937A0 (en) 1986-09-30
FI85334B (fi) 1991-12-31
ES8706443A1 (es) 1987-07-01
GB8612781D0 (en) 1986-07-02
NL8601354A (nl) 1986-12-16
DE3617753A1 (de) 1986-12-04
PT82647B (pt) 1989-01-30
GB2176703A (en) 1987-01-07
GB2176703B (en) 1988-12-07
DK163174C (da) 1992-06-22
DE3617753C2 (fr) 1988-06-30
HU200695B (en) 1990-08-28
FR2593393B1 (fr) 1989-06-02

Similar Documents

Publication Publication Date Title
BE904831A (fr) Composition d'activateur tissulaire du plasminogene.
US4530787B1 (fr)
PT788509E (pt) Derivados peptidicos terapeuticos
BE904830A (fr) Nouvelle composition d'activateur tissulaire du plasminogene.
FR2591485B1 (fr) Compositions stabilisees contenant l'activateur du plasminogene du tissu humain.
LV12000A (lv) Olbaltumviela ar uratoksidazes aktivitati un tas iegusana
DE3667490D1 (de) Herstellung von peptiden mit c-terminalem prolinamid.
SE8901552D0 (sv) Acid addition salts of amidated or glycine, their preparation and use
DK1897552T3 (da) Polymer-konjugeret glycosyleret neublastin
ATE24917T1 (de) Peptide-derivate, deren herstellung und verwendung als elastasehemmende mittel.
ES2124308T3 (es) Composicion estable de polipeptidos.
EP0326490A3 (en) Synthetic peptides and mixtures thereof for detecting hiv antibodies
KR950005325A (ko) 제약 조성물
ES2081797T3 (es) Aminoacidos y derivados peptidicos de 1,4-bis((aminoalquil e hidroxiaminoalquil)amino)-5,8-dihidroxiantraquinonas.
KR900001853A (ko) 변형된 인간 psti
SE8500093L (sv) Urokinasderivat
EA200001252A1 (ru) КОМПОЗИЦИЯ РЕКОМБИНАНТНОГО ИНТЕРФЕРОНА-β-1A(IFN-β-1A) ЧЕЛОВЕКА
ATE93731T1 (de) Protein enthaltende waesserige loesungen.
AU637997B2 (en) Pentamidine solutions for preventing pneumocystis carinii pneumonia
PT84011A (fr) Procede de preparation de nouveaux analogues de composes polypeptidiques hypocalcemiants epargnant de calcium de l:organisme
KR950018049A (ko) 사람 dna 토포이소머라제 제i형의 돌연변이체 단백질
ATE147268T1 (de) Hypoglycemische peptide
ATE432985T1 (de) Polypeptide mit aktivität der stimulierung von neutrophilen
KR970006314A (ko) 항균성 및 항진균성 활성을 갖는 폴리펩타이드
DK661888A (da) Biologisk aktive molekyler

Legal Events

Date Code Title Description
RE Patent lapsed

Owner name: THE WELLCOME FOUNDATION LTD

Effective date: 19950531